免疫检查点抑制剂疗法用于一名患有自身免疫性疾病和转移性皮肤鳞状细胞癌的肝移植受者。 - Suppr

Suppr

超能文献

Immune checkpoint inhibitor therapy in a liver transplant recipient with autoimmune disease and metastatic cutaneous squamous cell carcinoma.

作者信息

Brumfiel Caitlin M, Patel Meera H, Aqel Bashar, Lehrer Michael, Patel Samir H, Seetharam Mahesh

机构信息

Georgetown University School of Medicine, Washington, DC.

Creighton University School of Medicine, Phoenix Regional Campus, Phoenix, Arizona.

出版信息

JAAD Case Rep. 2021 Jun 4;14:78-81. doi: 10.1016/j.jdcr.2021.05.012. eCollection 2021 Aug.

DOI:10.1016/j.jdcr.2021.05.012

PMID:34277916

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8263514/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc5/8263514/fd41b4b76455/gr1.jpg

相似文献

Immune checkpoint inhibitor therapy in a liver transplant recipient with autoimmune disease and metastatic cutaneous squamous cell carcinoma.

JAAD Case Rep. 2021 Jun 4;14:78-81. doi: 10.1016/j.jdcr.2021.05.012. eCollection 2021 Aug.

Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy.

J Eur Acad Dermatol Venereol. 2022 Jan;36 Suppl 1:45-48. doi: 10.1111/jdv.17407.

Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives.

Clin Cosmet Investig Dermatol. 2023 Aug 9;16:2135-2142. doi: 10.2147/CCID.S381471. eCollection 2023.

Revision of immunosuppression in a solid organ transplant recipient leads to complete remission of metastatic undifferentiated carcinoma.

JAAD Case Rep. 2015 Nov 24;1(6):S8-S11. doi: 10.1016/j.jdcr.2015.09.010. eCollection 2015 Nov.

The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.

Oncologist. 2020 Jun;25(6):505-514. doi: 10.1634/theoncologist.2019-0659. Epub 2020 Feb 11.

Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry.

Cancer Med. 2021 Mar;10(6):2054-2062. doi: 10.1002/cam4.3802. Epub 2021 Feb 22.

Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa.

Case Rep Oncol. 2020 Jul 30;13(2):911-915. doi: 10.1159/000508933. eCollection 2020 May-Aug.

Remission of ulcerative colitis flare-up induced by nivolumab.

Int J Colorectal Dis. 2020 Sep;35(9):1791-1795. doi: 10.1007/s00384-020-03638-3. Epub 2020 May 26.

Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome.

J Immunother Cancer. 2019 Dec 4;7(1):338. doi: 10.1186/s40425-019-0801-z.

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.

BMC Cancer. 2020 Mar 18;20(1):230. doi: 10.1186/s12885-020-06727-2.

引用本文的文献

Treatment with programmed-death-1 inhibitors for non-melanoma skin cancer among immunocompromised patients with subgroup analysis of solid organ transplant patients.

Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyaf022.

Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors.

Cancers (Basel). 2024 Jun 28;16(13):2374. doi: 10.3390/cancers16132374.

Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies.

Front Transplant. 2023 Oct 30;2:1284740. doi: 10.3389/frtra.2023.1284740. eCollection 2023.

Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data.

Cancers (Basel). 2023 Sep 15;15(18):4574. doi: 10.3390/cancers15184574.

Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?

Front Immunol. 2023 Feb 16;14:1092401. doi: 10.3389/fimmu.2023.1092401. eCollection 2023.

Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis.

Liver Int. 2023 Jan;43(1):8-17. doi: 10.1111/liv.15419. Epub 2022 Sep 27.

本文引用的文献

Immune checkpoint inhibitors to treat cutaneous malignancies.

J Am Acad Dermatol. 2020 Nov;83(5):1239-1253. doi: 10.1016/j.jaad.2020.03.131. Epub 2020 May 24.

The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial.

Vaccines (Basel). 2020 Apr 20;8(2):191. doi: 10.3390/vaccines8020191.

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.

Eur J Cancer. 2020 Mar;128:83-102. doi: 10.1016/j.ejca.2020.01.008. Epub 2020 Feb 26.

The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.

Oncologist. 2020 Jun;25(6):505-514. doi: 10.1634/theoncologist.2019-0659. Epub 2020 Feb 11.

Next-generation sequencing for the general cancer patient.

Clin Adv Hematol Oncol. 2019 Aug;17(8):447-454.

Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review.

J Am Acad Dermatol. 2020 Jun;82(6):1490-1500. doi: 10.1016/j.jaad.2019.07.005. Epub 2019 Jul 11.

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation.

Front Oncol. 2018 Dec 13;8:612. doi: 10.3389/fonc.2018.00612. eCollection 2018.

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.

Ann Oncol. 2019 Jan 1;30(1):44-56. doi: 10.1093/annonc/mdy495.

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.

Ann Intern Med. 2018 Jan 16;168(2):121-130. doi: 10.7326/M17-2073. Epub 2018 Jan 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验